A retrospective study for the treatments and prognosis of brain metastases of gynecologic malignancies
Not Applicable
- Conditions
- Brain metastases of gynecologic malignancies diagnosed with imaging modalities
- Registration Number
- JPRN-UMIN000003542
- Lead Sponsor
- Kansai Clinical Oncology Group
- Brief Summary
Mean survival time of the patients with brain metastases was 12.5 months for the ovarian cancer group, 6.2 months for the corpus cancer group, and 5.0 months for the cervical cancer group; two-year overall survival rates were 19.7%, 6.1%, and 4.8%, respectively. Multivariate analysis revealed ovarian/tubal/peritoneal origin, KPS >70, single brain metastasis, absence of extracranial disease, cranial surgery, cranial radiotherapy, and chemotherapy to be independent favorable prognostic factors associated with overall survival.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Petients with history of non-gynecologic malignancies Ptients with active non-gynecologic malignancy Choriocarcinoma Petients with history of treatment for central nervous system disease
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Age at diagnosis Duration from the initial diagnosis to the recurrence Duration from the initial diagnosis to the detection of brain metastases Sites of brain metastases Site and stage of primary disease Pathological diagnosis of primary disease Complication Initial treatment for the primary disease Effects of primary chemotherapy Presence of pulmonary metastases Sites of recurrence Symptoms at recurrence Neurological findings at diagnosis of brain metastases Karnofsky Performance Status (KPS) and Recursive Partitioning Analysis (RPA) Imaging modalities for the diagnosis of brain metastases Numbers, Sites and size of brain metastases Treatment modalities for brain metastases and their therapeutic effects and adverse effects Status of neurologic symptoms after treatments Prognosis Cause of death
- Secondary Outcome Measures
Name Time Method